1. Surveillance for Nonmuscle Invasive Bladder Cancer: Identifying the Point of Diminishing Returns.
- Author
-
Ranti D, Dey L, Bieber C, Grauer R, Rich J, Rosenzweig S, Koskela LR, Steineck G, Hosseini A, Egevad L, Patrakka J, Attalla K, Wiklund P, Sfakianos J, and Waingankar N
- Subjects
- Humans, Male, Female, Muscles, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms epidemiology, Urinary Bladder Neoplasms therapy
- Abstract
Objective: To characterize first and second recurrence patterns using 26years of cohort-level follow-up and microsimulation modeling., Methods: Patients diagnosed with nonmuscle-invasive bladder cancer in Stockholm County between 1995 and 1996 were included. Clinical, pathological, and longitudinal follow-up data were gathered. Logistic regressions, Kaplan Meier curves, and Cox proportional hazards models were run to generate assumptions for a microsimulation model, simulating first and second recurrence and progression for 10,000 patients., Results: Three hundred eighty-six patients were included: 67.4% were male; >50% were TaLG; and 37.5% were American Urological Association high-risk. Median time to recurrence was 300days. Three patients had missing data. Cohort follow-up has been carried out for 26years. For simulated first-recurrences, low-risk patients recurred at 56.6% over 15years of follow-up, with 2.2% muscle-invasive (MI) progression; intermediate-risk patients recurred at 62.8%, with 4.3% MI progression; high-risk patients recurred at 48.7% over 15years, with MI progression at 14.3%. For second recurrences, 70.7%, 75.7%, and 84.7% of low, medium, and high-risk patients recurred. No patients were seen to have first recurrences after 9years, with low, but notable, rates beyond 5years., Conclusion: These data suggest that low-, intermediate-, and high-risk patients without recurrence at 5years may be potentially transitioned to less invasive monitoring., Competing Interests: Declaration of Competing Interest The authors have no conflict of interest to declare., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF